Polypeptide complex extracted from porcine/bovine cerebral cortex tissue. Contains multiple neurotrophic peptides. Studied for childhood cognitive development, stroke rehabilitation, and neuroprotection in Russia and Eastern Europe.
Cortexin is a polypeptide complex extracted from the cerebral cortex of young pigs or cattle. It has been studied primarily in Russia and Eastern Europe for neuroprotection, cognitive support, and recovery from neurological conditions including stroke and traumatic brain injury. Like cerebrolysin, it is a complex mixture rather than a single defined compound.
Stroke Recovery Research
Russian clinical studies have examined cortexin in ischemic stroke patients. Published data suggest improvements in neurological deficit scores and functional recovery, particularly when started in the acute or subacute phase after stroke. It is used clinically in Russia for this purpose.
Cognitive and Neuroprotective Research
Research has examined cortexin in age-related cognitive decline and conditions involving neuronal loss. Some trials report improvements in cognitive function tests, though the quality and scale of these studies vary widely.
Traumatic Brain Injury
Some research has examined cortexin for supporting recovery after brain injury. As with other applications, the published evidence comes predominantly from Russian institutions and has not been replicated in large Western trials.
Russian clinical studies report improvements in neurological recovery after stroke.
Some evidence of cognitive improvements in trials of elderly patients with cognitive decline.
Neuroprotective effects in animal models of brain injury.
Not evaluated in large Western randomized controlled trials.
The research base for cortexin shares many of the limitations of cerebrolysin — most published data come from Russian and Eastern European research programs that have not been independently replicated in large Western trials with rigorous methodology. The compound is a complex mixture of peptides that is difficult to standardize and characterize. It is not FDA-approved and would be considered experimental outside of the countries where it is clinically used.
Cortexin is produced by taking the cerebral cortex of young animals, extracting the proteins, and breaking them down into short peptide fragments. The idea is that these fragments resemble naturally occurring neurotrophic peptides — the signals that neurons use to communicate survival and growth instructions. When administered, these fragments are thought to cross into brain tissue and support neuronal survival, reduce inflammation, and activate repair mechanisms. The exact mechanisms are not fully characterized because it is a complex mixture rather than a single compound with an identified receptor target.
In published studies, cortexin has been reported as well-tolerated. Because it is an animal-derived product, there are theoretical concerns about contamination, though manufacturing processes are designed to address this. It is not FDA-approved. Outside of Russia and a few other countries, it should be considered investigational with limited independent safety validation.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
10mg/day IM for 10 days in published Russian/Eastern European trials
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Cortexin in Neurological Practice: Review of Clinical Evidence
Perinatal encephalopathy, the syndrome of intracranial hypertension and associated diagnostic labels in the Commonwealth of Independent States: a systematic review
Activation of Cytosolic Cathepsin B Activity in the Brain by Traumatic Brain Injury and Inhibition by the Neutral pH Selective Inhibitor Probe Z-Arg-Lys-AOMK
Transcriptomes Suggest That Pinniped and Cetacean Brains Have a High Capacity for Aerobic Metabolism While Reducing Energy-Intensive Processes Such as Synaptic Transmission
Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.